SKU: C282  / 
    CAS Number: 55268-75-2

    Cefuroxime Free Acid

    $121.00 - $400.00

    Cefuroxime is a semi-synthetic, broad-spectrum, β-lactamase-resistant, second-generation cephalosporin. The compound was patented in 1971. It has increased stability to β-lactamases, which can widen the spectrum so that many organisms that are resistant to cephalosporins in general are susceptible to Cefuroxime.

    Cefuroxime is soluble in water

    Mechanism of Action Cephalosporins interfere with PBP (penicillin binding protein) activity involved in the final phase of peptidoglycan synthesis. PBPs are enzymes which catalyze a pentaglycine crosslink between alanine and lysine residues providing additional strength to the cell wall. Without a pentaglycine crosslink, the integrity of the cell wall is severely compromised and ultimately leads to cell lysis and death. Resistance to cephalosporins is commonly due to cells containing plasmid encoded β-lactamases.

    Spectrum It is rapidly bactericidal against Gram-positive bacteria, including penicillinase-producing staphylococci and a wide range of Gram-negative organisms including non-β-lactamase-producing strains. Unlike the majority of cephalosporins, Cefuroxime is highly active agaisnt strains of Haemophilus influenzae, and this activity is maintained against the ampicillin-resistant strains. Ampicillin resistance is due to the production of class III β-lactamase, to which Cefuroxime is completely stable.
    Microbiology Applications Cefuroxime is used in clinical in vitro microbiological antimicrobial susceptibility tests (panels, discs, and MIC strips) against Gram-positive and Gram-negative isolates. Medical microbiologists use AST results to recommend antibiotic treatment options.  Representative MIC values include:

    Haemophilus influenzae: <0.06 - 16 µg/ml
    Streptococcus pneumoniae: 0.004 - 0.25 µg/ml

    For a representative list of MIC values, click here

    Molecular Formula C16H16N4O8S

    Ballestero-Tellez M et al (2020) Inter-technique variability between antimicrobial susceptibility testing methods affects clinical classification of Cefuroxime in strains close to breakpoint. Clinc. Microbiol. Infect. Res Note 26(5):P648. E1-648. E3

    O'Callaghan CH, Sykes RB, Griffiths A, Thornton JE (1976) Cefuroxime, a new cephalosporin antibiotic: Activity in vitro. Antimicrob. Agents Chemother. 9(3):511-519 PMID 1259407